• 1
    Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:21972223.
  • 2
    Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646657.
  • 3
    Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. Lancet Neurol 2002;1:3743.
  • 4
    Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:24432454.
  • 5
    Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. Eur J Neurol 2012;19:155162.
  • 6
    Shapiro R, Goadsby P. The long drought: the dearth of public funding for headache research. Cephalalgia 2007;27:991994.
  • 7
    Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. N Engl J Med 2002;346:257270.
  • 8
    Charles A. Migraine: a brain state. Curr Opin Neurol 2013;26:235239.
  • 9
    Gowers WR. A manual of diseases of the nervous system. 3rd ed. Philadelphia, PA: P. Blakiston, Son & Co, 1899:1357.
  • 10
    Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629808.
  • 11
    Diener H-C, Dodick D, Goadsby PJ, et al. Chronic migraine-classification, characteristics and treatment. Nat Rev Neurol 2012;14:162171.
  • 12
    Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache 2011;51:10581077.
  • 13
    Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996;87:543552.
  • 14
    van den Maagdenberg AMJM, Pietrobon D, Pizzorusso T, et al. A Cacna1a knock-in migraine mouse model with increased susceptibility to cortical spreading depression. Neuron 2004;41:701710.
  • 15
    Eikermann-Haerter K, Dilekoz E, Kudo C, et al. Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. J Clin Invest 2009;119:99109.
  • 16
    Brennan KC, Romero-Reyes M, Lopez Valdes HE, et al. Reduced threshold for cortical spreading depression in female mice. Ann Neurol 2007;61:603606.
  • 17
    Leao AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol 1944;7:359390.
  • 18
    Leao AP, Morison RS. Propagation of spreading cortical depression. J Neurophysiol 1945;8:3345.
  • 19
    Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994;117:199210.
  • 20
    Ayata C, Jin H, Kudo C, et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006;59:652661.
  • 21
    Brennan KC, Beltran-Parrazal L, Lopez Valdes HE, et al. Distinct vascular conduction with cortical spreading depression. J Neurophysiol 2007;97:41434151.
  • 22
    Brennan KC, Bates EA, Shapiro RE, et al. Casein kinase iδ mutations in familial migraine and advanced sleep phase. Sci Transl Med 2013;5:183ra56.
  • 23
    Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938;39:737763.
  • 24
    Charles A. Vasodilation out of the picture as a cause of migraine headache. Lancet Neurol 2013;12:419420.
  • 25
    Amin FM, Asghar MS, Hougaard A, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol 2013;12:454461.
  • 26
    Ahn AH. On the temporal relationship between throbbing migraine pain and arterial pulse. Headache 2010;50:15071510.
  • 27
    Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. J Neurosci 1987;7:41294136.
  • 28
    Peroutka SJ. Neurogenic inflammation and migraine: implications for therapeutics. Mol Interv 2005;5:306313.
  • 29
    Palm-Meinders IH, Koppen H, Terwindt GM, et al. Structural brain changes in migraine. JAMA 2012;308:18891897.
  • 30
    Kurth T, Mohamed S, Maillard P, et al. Headache, migraine, and structural brain lesions and function: population based Epidemiology of Vascular Ageing-MRI study. BMJ 2011;342:c7357.
  • 31
    Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry 1960;23:2332.
  • 32
    Lipton RB, Bigal ME, Ashina S, et al. Cutaneous allodynia in the migraine population. Ann Neurol 2008;63:148158.
  • 33
    Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack. Brain 2000;123:17031709.
  • 34
    Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004;55:1926.
  • 35
    Jakubowski M, Levy D, Goor-Aryeh I, et al. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005;45:850861.
  • 36
    Akerman S, Holland P, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011;12:570584.
  • 37
    Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;1:658660.
  • 38
    Afridi S, Giffin NJ, Kaube H, et al. A PET study in spontaneous migraine. Arch Neurol 2005;62:12701275.
  • 39
    Denuelle M, Fabre N, Payoux P, et al. Brainstem and hypothalamic activation in spontaneous migraine attacks. Cephalalgia 2004;24:775814.
  • 40
    Afridi S, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 2005;128:932939.
  • 41
    Maniyar FH, Sprenger T, Schankin C, et al. Investigating the premonitory phase of migraine with H215O PET. Cephalalgia 2013;33:12.
  • 42
    Charbit AR, Akerman S, Holland PR, Goadsby PJ. Neurons of the dopaminergic/CGRP A11 cell group modulate neuronal firing in the trigeminocervical complex: an electrophysiological and immunohistochemical study. J Neurosci 2009;29:1253212541.
  • 43
    Knight YE, Bartsch T, Kaube H, Goadsby PJ. P/Q-type calcium channel blockade in the PAG facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci 2002;22:16.
  • 44
    Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000;62:509525.
  • 45
    Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6:761766.
  • 46
    Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993;109:788792.
  • 47
    Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 2004;142:11711181.
  • 48
    Shields KG, Goadsby PJ. Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol Dis 2006;23:491501.
  • 49
    Summ O, Charbit AR, Andreou AP, Goadsby PJ. Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain 2010;133:25402548.
  • 50
    Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT1B/1D receptors in the periaqueductal grey inhibits meningeal nociception. Ann Neurol 2004;56:371381.
  • 51
    Holland PR, Akerman S, Lasalandra MP, Goadsby PJ. Orexin A antinociceptive effects in the ventrolateral periaqueductal gray are blocked by 5HT1B/1D receptor antagonism. Ann Neurol 2008;64:S26.
  • 52
    Pozo-Rosich P, Storer RJ, Goadsby PJ. Calcitonin gene-related peptide (CGRP) and its receptor antagonists BIBN4096BS (olcegepant) and CGRP (8–37) can modulate neuronal activity of the trigeminocervical complex of the rat when microinjected into the ventrolateral periaqueductal gray. Cephalalgia 2009;29:45.
  • 53
    Vermeersch SGG, de Hoon J, De Saint-Hubert B, et al. PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy. J Headache Pain 2013;1:P224.
  • 54
    Lance JW, Goadsby PJ. Mechanism and management of headache. 7th ed. New York, NY: Elsevier, 2005.
  • 55
    Lipton RB, Bigal M. Migraine and other headache disorders. 1st ed. New York, NY: Marcel Dekker, Taylor & Francis Books, 2006.
  • 56
    Olesen J, Tfelt-Hansen P, Ramadan N, et al. The headaches. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
  • 57
    Goadsby PJ, Sprenger T. Current practice and future directions in the management of migraine: acute and preventive. Lancet Neurol 2010;9:285298.
  • 58
    Coppola G, Pierelli F, Schoenen J. Habituation and migraine. Neurobiol Learn Mem 2009;92:249259.
  • 59
    Gantenbein A, Sandor PS, Fritschy J, et al. Sensory information processing may be neuroenergetically more demanding in migraine patients. Neuroreport 2013;24:202205.
  • 60
    Goadsby PJ. Trigeminal autonomic cephalalgias. Continuum (Minneap Minn) 2012;18:883895.
  • 61
    Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin, 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:16681675.
  • 62
    Silberstein SD, Olesen J, Bousser MG, et al. The International Classification of Headache Disorders, 2nd Edition (ICHD-II)—revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 2005;25:460465.
  • 63
    Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008;48:11571168.
  • 64
    De Felice M, Porreca F. Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache. Cephalalgia 2009;29:12771284.
  • 65
    De Felice M, Ossipov MH, Wang R, et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol 2010;67:325337.
  • 66
    De Felice M, Ossipov MH, Wang R, et al. Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain 2011;133:2477.
  • 67
    Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003;289:6569.
  • 68
    Stovner LJ, Linde M, Gravdahl GB, et al. Candesartan versus propranolol for migraine prophylaxis: a randomized, triple-blind, placebo-controlled, double crossover study. Cephalalgia 2013;33:13.
  • 69
    Diener HC, Gendolla A, Feuersenger A, et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia 2009;29:921927.
  • 70
    Bussone G, Diener H-C, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blinded randomised controlled trials. Int J Clin Pract 2005;59:961968.
  • 71
    Silberstein S, Saper J, Berenson F, et al. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology 2008;70:548555.
  • 72
    Cady RK, Mathew N, Diener HC, et al. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache 2009;49:216226.
  • 73
    Dodick D, Lipton RB, Martin V, et al. Consensus statement: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004;44:414425.
  • 74
    Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183187.
  • 75
    Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurol 1988;23:193196.
  • 76
    Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:4856.
  • 77
    Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:11041110.
  • 78
    Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:21152123.
  • 79
    Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist, MK-3207, in the acute treatment of migraine. Cephalalgia 2011;31:712722.
  • 80
    Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000;129:420423.
  • 81
    Ferrari MD, Farkkila M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan—a randomised proof-of-concept trial. Cephalalgia 2010;30:11701178.
  • 82
    Farkkila M, Diener HC, Geraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012;11:405413.
  • 83
    Afridi S, Giffin NJ, Kaube H, Goadsby PJ. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 2013;80:642647.
  • 84
    Goadsby PJ, Keywood C. Investigation of the role of mGluR5 inhibition in migraine: a proof of concept study of ADX10059 in acute treatment of migraine. Neurology 2009;72:A285.
  • 85
    Goadsby PJ, Ferrari MD, Csanyi A, et al. Randomized double blind, placebo-controlled proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 2009;29:742750.
  • 86
    Hauge AW, Asghar MS, Schytz HW, et al. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol 2009;8:718723.
  • 87
    Mohammed BP, Goadsby PJ, Prabhakar P. Safety and efficacy of flunarizine in childhood migraine: report of 11 years' experience, with emphasis on its effect in hemiplegic migraine. Dev Med Child Neurol 2012;54:274277.
  • 88
    Goldstein DJ, Wang O, Saper JR, et al. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 1997;17:785790.
  • 89
    Norman B, Panebianco D, Block GA. A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine. Cephalalgia 1998;18:407.
  • 90
    Connor HE, Bertin L, Gillies S, et al. Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine. Cephalalgia 1998;18:392.
  • 91
    Diener H-C, the RPR100893 Study Group. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 2003;23:183185.
  • 92
    Goldstein DJ, Offen WW, Klein EG, et al. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 2001;21:102106.
  • 93
    May A, Gijsman HJ, Wallnoefer A, et al. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996;67:375378.
  • 94
    Data J, Britch K, Westergaard N, et al. A double-blind study of ganaxolone in the acute treatment of migraine headaches with or without an aura in premenopausal females. Headache 1998;38:380.
  • 95
    Palmer JE, Guillard FL, Laurijssens BE, et al. A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia 2009;29:124.
  • 96
    Hoye K, Laurijssens BE, Harnisch LO, et al. Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine. Cephalalgia 2009;29:132.
  • 97
    Maleki N, Linnman C, Brawn J, et al. Her versus his migraine: multiple sex differences in brain function and structure. Brain 2012;135:25462559.
  • 98
    Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990;16:6975.
  • 99
    Zagami AS, Edvinsson L, Hoskin KL, Goadsby PJ. Stimulation of the superior sagittal sinus causes extracranial release of PACAP. Cephalalgia. 1995;15(suppl 14):109.
  • 100
    Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 2013;33:10851095.
  • 101
    Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept 1992;37:287303.
  • 102
    Harmar AJ, Fahrenkrug J, Gozes I, et al. IUPHAR Reviews 1: pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Br J Pharmacol 2012;166:417.
  • 103
    Chan KY, Baun M, de Vries R, et al. Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia 2001;31:181189.
  • 104
    Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 1996;16:310316.
  • 105
    Akerman S, Goadsby PJ. VPAC1 and PAC1 receptor antagonists inhibit activation of the parasympathetic outflow to the cranial vasculature to prevent autonomic responses and neuronal firing in the trigeminocervical complex. Cephalalgia 2009;29:130.
  • 106
    Uddman R, Tajti J, Hou M, et al. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 2002;22:112116.
  • 107
    Csati A, Tajti J, Kuris A, et al. Distribution of vasoactive intestinal polypeptide, pituitary adenylate cyclase activating peptide, nitric oxide synthase and their receptors in human and rat sphenopalatine ganglion. Neuroscience 2012;202:158168.
  • 108
    Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009;132:1625.
  • 109
    Amin FM, Asghar MS, Guo S, et al. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 2012;32:140149.
  • 110
    Hansen JM, Sitarz J, Birk S, et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia 2006;26:9921003.
  • 111
    Rahmann A, Wienecke T, Hansen JM, et al. Vasoactive intestinal peptide causes marked cephalic vasodilatation but does not induce migraine. Cephalalgia 2008;28:226236.
  • 112
    Summ O, Akerman S, Holland PR, Goadsby PJ. TRPV1 receptor blockade is ineffective in different in vivo models of migraine. Cephalalgia 2011;31:172180.
  • 113
    Rami HK, Thompson M, Stemp G, et al. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 2006;16:32873291.
  • 114
    Hoffmann J, Supronsinchai W, Andreou AP, et al. Olvanil acts on TRPV1 and CB1 receptors to modulate neuronal transmission in the trigeminovascular system. Pain 2012:22262232.
  • 115
    Albrecht S, Denner AC, Eberhardt M, et al. Role for TRPA1 receptor channels in trigeminal afferent activation and neuropeptide release from rat cranial dura mater. J Headache Pain 2013;1:P70.
  • 116
    Barrett SA, Gifford EW. Miwok material culture. Bull Public Museum City Milwaukee 1933;2:117376.
  • 117
    Nassini R, Materazzi S, Vriens J, et al. The ‘headache tree’ via umbellulone and TRPA1 activates the trigeminovascular system. Brain 2012;135:376390.
  • 118
    Chasman DI, Schurks M, Anttila V, et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet 2011;43:695698.
  • 119
    Freilinger T, Anttila V, de Vries B, et al. Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat Genet 2012;44:777782.
  • 120
    Anttila V, Stefansson H, Kallela M, et al. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet 2010;42:869873.
  • 121
    Peier AM, Moqrich A, Hergarden AC, et al. A TRP channel that senses cold stimuli and menthol. Cell 2002;108:705715.
  • 122
    Kellenberger S, Schild L. Epithelial sodium channel/degenerin family of ion channels: a variety of functions for a shared structure. Physiol Rev 2002;82:735767.
  • 123
    Ziemann AE, Schnizler MK, Albert GW, et al. Seizure termination by acidosis depends on ASIC1a. Nat Neurosci 2008;11:816822.
  • 124
    Friese MA, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med 2007;13:14831489.
  • 125
    Holland PR, Akerman S, Andreou AP, et al. Acid-sensing ion channel-1: a novel therapeutic target for migraine with aura. Ann Neurol 2012;72:559563.
  • 126
    Diochot S, Baron A, Salinas M, et al. Black mamba venom peptides target acid-sensing ion channels to abolish pain. Nature 2012;490:552555.
  • 127
    Goadsby PJ, Raskin NH. Headache. In: Longo DL, Fauci AS, Kasper DL, et al, eds. Harrison's principles of internal medicine. New York, NY: McGraw Hill Medical, 2012:112128.
  • 128
    Gelfand AA, Goadsby PJ. A neurologist's guide to acute migraine therapy in the emergency room. Neurohospitalist 2012;2:5159.
  • 129
    Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache 2011;51:507517.
  • 130
    Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 2007;297:14431454.
  • 131
    Goldstein J, Smith TR, Pugach N, et al. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache 2012;52:14021410.
  • 132
    Brandes JL, Cady RK, Freitag FG, et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 2009;49:14351444.
  • 133
    Peres MF, Goncalves AL. Double-blind, placebo controlled, randomized clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. Neurology 2013:S40.005.
  • 134
    Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921936.
  • 135
    Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo-controlled, dose-ranging trial. Cephalalgia 2013;33:94.
  • 136
    Diener H-C, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the acute treatment of migraine attacks: results from a phase II study. Cephalalgia 2011;31:573584.
  • 137
    Medve RA, Andrews JS. Effects of fixed dose combination of nNOS inhibition and 5HT agonism on progression of migraine with and without aura. Cephalalgia 2009;29:126.
  • 138
    de Hoon J, Montieth D, Vermeersch S, et al. Safety, pharmacokinetics, and pharmacodynamics of LY2951742: a monoclonal antibody targeting CGRP. Cephalalgia 2013;33:247248.
  • 139
    Garzone P, Shelton D, Wong G, et al. Safety, tolerability, and pharmacokinetics of LBR-101 (RN-307or PF-04427429) after multiple intravenous injections—a randomized, double-blind, placebo controlled study. Cephalalgia 2013;33:966.
  • 140
    Liu H, Xu C, Shi L, et al. Immunohistochemical localization of the CLR/RAMP1 receptor complex in the trigeminovascular system of the cynomolgus monkey. Headache 2011;51:5.
  • 141
    Winrow CJ, Gotter AL, Cox CD, et al. Pharmacological characterization of MK-6096—a dual orexin receptor antagonist for insomnia. Neuropharmacology 2012;62:978987.
  • 142
    Sang CN, Ramadan NM, Wallihan RG, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004;24:596602.
  • 143
    Johnson KW, Nisenbaum ES, Johnson MP, et al. Innovative drug development for headache disorders: glutamate. In: Olesen J, Ramadan N, eds. Innovative drug development for headache disorders. Vol 16. Oxford, UK: Oxford University Press, 2008:185194.
  • 144
    Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol 2010;9:373380.
  • 145
    Saper J, Dodick DW, Silberstein S, et al. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 2011;41:271285.
  • 146
    Silberstein SD, Goode-Sellers S, Twomey CK, et al. Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia 2013;33:101111.
  • 147
    Lipton RB, Goadsby PJ, Cady RK, et al. PRISM study: occipital nerve stimulation for treatment-refractory migraine. Cephalalgia 2009;29:30.
  • 148
    Goadsby PJ, Grosberg BM, Mauskop A, Cady R. Non-invasive vagus nerve stimulation (nVNS) for acute treatment of migraine: an open-label pilot study. Neurology 2013:S40.004.
  • 149
    Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 2013;80:697704.
  • 150
    Schoenen J, Jensen RH, Lanteri-Minet M, et al. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment—pathway CH-1: a randomized, sham-controlled study. Cephalalgia 2013;33:816830.